Literature DB >> 8044934

Ca(2+)-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium.

M A Movsesian1, M Karimi, K Green, L R Jones.   

Abstract

BACKGROUND: Observations of abnormalities in the diastolic components of intracellular Ca2+ transients in failing human left ventricular myocardium have raised the possibility that reductions in the level or function of sarcoplasmic reticulum proteins involved in Ca2+ transport contribute to the pathophysiology of dilated cardiomyopathy in humans. Functional assays, however, have revealed no differences in ATP-dependent Ca2+ transport or its modulation by phospholamban in sarcoplasmic reticulum-enriched microsomes prepared from nonfailing and failing human left ventricular myocardium. The purpose of the present study was to quantify protein levels of Ca(2+)-transporting ATPase, phospholamban, and calsequestrin directly in nonfailing and failing human left ventricular myocardium. METHOD AND
RESULTS: Total protein extracts were prepared from nonfailing left ventricular myocardium from the hearts of unmatched organ donors with normal left ventricular contractility (n = 6) and from failing left ventricular myocardium from the excised hearts of transplant recipients with class IV heart failure resulting from idiopathic dilated cardiomyopathy (n = 6). Ca(2+)-transporting ATPase, phospholamban, and calsequestrin contents were determined by quantitative immunoblotting with monoclonal and affinity-purified polyclonal antibodies. The levels of the three proteins were identical in nonfailing and failing human left ventricular myocardium.
CONCLUSIONS: These results indicate that protein levels of Ca(2+)-transporting ATPase, phospholamban, and calsequestrin are not diminished in failing human left ventricular myocardium and that downregulation of the Ca(2+)-transporting ATPase and phospholamban is not part of the molecular pathophysiology of dilated cardiomyopathy in humans.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8044934     DOI: 10.1161/01.cir.90.2.653

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

1.  Kinetics studies of the cardiac Ca-ATPase expressed in Sf21 cells: new insights on Ca-ATPase regulation by phospholamban.

Authors:  J E Mahaney; J M Autry; L R Jones
Journal:  Biophys J       Date:  2000-03       Impact factor: 4.033

2.  Characterizing phospholamban to sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a) protein binding interactions in human cardiac sarcoplasmic reticulum vesicles using chemical cross-linking.

Authors:  Brandy L Akin; Larry R Jones
Journal:  J Biol Chem       Date:  2012-01-14       Impact factor: 5.157

3.  Diminished post-rest potentiation of contractile force in human dilated cardiomyopathy. Functional evidence for alterations in intracellular Ca2+ handling.

Authors:  B Pieske; M Sütterlin; S Schmidt-Schweda; K Minami; M Meyer; M Olschewski; C Holubarsch; H Just; G Hasenfuss
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

4.  Oxidative posttranslational modifications mediate decreased SERCA activity and myocyte dysfunction in Galphaq-overexpressing mice.

Authors:  Steve Lancel; Fuzhong Qin; Shannon L Lennon; Jingmei Zhang; Xiaoyong Tong; Michael J Mazzini; Y James Kang; Deborah A Siwik; Richard A Cohen; Wilson S Colucci
Journal:  Circ Res       Date:  2010-05-27       Impact factor: 17.367

5.  Enhanced ryanodine receptor-mediated calcium leak determines reduced sarcoplasmic reticulum calcium content in chronic canine heart failure.

Authors:  Andriy Belevych; Zuzana Kubalova; Dmitry Terentyev; Robert L Hamlin; Cynthia A Carnes; Sandor Györke
Journal:  Biophys J       Date:  2007-09-07       Impact factor: 4.033

6.  Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts.

Authors:  S Bartel; B Stein; T Eschenhagen; U Mende; J Neumann; W Schmitz; E G Krause; P Karczewski; H Scholz
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

Review 7.  Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure.

Authors:  W Schmitz; P Boknik; B Linck; F U Müller
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

8.  Calcium handling proteins: structure, function, and modulation by exercise.

Authors:  Jamille Locatelli; Leonardo V M de Assis; Mauro C Isoldi
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

Review 9.  Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy.

Authors:  Changwon Kho; Ahyoung Lee; Roger J Hajjar
Journal:  Nat Rev Cardiol       Date:  2012-10-23       Impact factor: 32.419

Review 10.  Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium.

Authors:  Francesco S Loffredo; Andriana P Nikolova; James R Pancoast; Richard T Lee
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.